Kanjinti (Trastuzumab-Anns) for Breast Cancer

Overview
Kanjinti is approved by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-overexpressing breast cancer. This medication is indicated for people with tumors that produce high levels of the HER2 protein. It may be used in early breast cancer or in cases where the cancer has metastasized (spread) to other parts of the body. Kanjinti is also known by its drug name, Trastuzumab-anns.

Kanjinti is a biologic drug, specifically a HER2/neu receptor antagonist. It works by attaching to the HER2 protein on the surface of cancer cells, blocking them from receiving growth signals, and helping the immune system destroy these cells.

How do I take it?
Prescribing information states that Kanjinti is given as an intravenous (IV) infusion. For early breast cancer, the initial dose is usually administered over 90 minutes, followed by a weekly dose over 30 minutes for 12 to 18 weeks. After this, a dose is administered over 30 to 90 minutes every three weeks for up to 52 weeks. For metastatic breast cancer, the initial dosing is administered over 90 minutes, followed by weekly doses over 30 minutes. It should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Kanjinti include headache, diarrhea, nausea, chills, fever, infection, congestive heart failure, insomnia, cough, and rash.

Rare but serious side effects may include cardiomyopathy (heart muscle disease), severe allergic reactions (such as anaphylaxis and angioedema), interstitial pneumonitis (lung inflammation), acute respiratory distress syndrome (severe lung condition), and embryo-fetal toxicity (harm to an unborn baby).

For more information about this treatment, visit:

Label: Kanjinti — Trastuzumab-Anns Injection, Powder, Lyophilized, for Solution

Kanjinti — Drugs.com